Pharnext SA

XPAR:ALPHA (France)  
€ 0.04 (+14.38%) Jun 7
At Loss
Market Cap:
€ 214.00K ($ 231.00K)
Enterprise V:
€ 26.37M ($ 28.52M)
Volume:
927.85K
Avg Vol (2M):
222.84K
Also Trade In:
Volume:
927.85K
At Loss
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Pharnext ( XPAR:ALPHA ) from 2016 to Jun 09 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Pharnext stock (XPAR:ALPHA) PE ratio as of Jun 09 2024 is 0. More Details

Pharnext SA (XPAR:ALPHA) PE Ratio (TTM) Chart

To

Pharnext SA (XPAR:ALPHA) PE Ratio (TTM) Historical Data

Total 1289
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Pharnext PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-10 At Loss 2024-04-05 At Loss
2024-06-07 At Loss 2024-04-04 At Loss
2024-06-06 At Loss 2024-04-03 At Loss
2024-06-05 At Loss 2024-04-02 At Loss
2024-06-04 At Loss 2024-03-28 At Loss
2024-06-03 At Loss 2024-03-27 At Loss
2024-05-31 At Loss 2024-03-26 At Loss
2024-05-30 At Loss 2024-03-25 At Loss
2024-05-29 At Loss 2024-03-22 At Loss
2024-05-28 At Loss 2024-03-21 At Loss
2024-05-27 At Loss 2024-03-20 At Loss
2024-05-24 At Loss 2024-03-19 At Loss
2024-05-23 At Loss 2024-03-18 At Loss
2024-05-22 At Loss 2024-03-15 At Loss
2024-05-21 At Loss 2024-03-14 At Loss
2024-05-20 At Loss 2024-03-13 At Loss
2024-05-17 At Loss 2024-03-12 At Loss
2024-05-16 At Loss 2024-03-11 At Loss
2024-05-15 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-03-01 At Loss
2024-05-07 At Loss 2024-02-29 At Loss
2024-05-06 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss

Pharnext SA (XPAR:ALPHA) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Pharnext SA is a biopharmaceutical company developing treatments targeting neurodegenerative diseases. The company also develop a Pleotherapy technology platform. Its product in the pipeline includes SYNGILITY; PXT3003 and PXT864. The company's only segment being research and development on new pharmaceutical therapies based on Pleotherapy.